Update in ARDS management: recent randomized controlled trials that changed our practice.
Identifieur interne : 000388 ( Main/Exploration ); précédent : 000387; suivant : 000389Update in ARDS management: recent randomized controlled trials that changed our practice.
Auteurs : J Fernando Santacruz [États-Unis] ; Enrique Diaz Guzman Zavala ; Alejandro C. ArroligaSource :
- Cleveland Clinic journal of medicine [ 0891-1150 ] ; 2006.
Descripteurs français
- KwdFr :
- Décubitus ventral (MeSH), Essais contrôlés randomisés comme sujet (MeSH), Glycine (analogues et dérivés), Glycine (usage thérapeutique), Humains (MeSH), Inhibiteurs de la sérine protéinase (usage thérapeutique), Monoxyde d'azote (usage thérapeutique), Ohio (MeSH), Sulfonamides (usage thérapeutique), Syndrome de détresse respiratoire de l'adulte (thérapie), Syndrome de détresse respiratoire de l'adulte (traitement médicamenteux), Taux de survie (MeSH), Ventilation liquide (MeSH), Ventilation à haute fréquence (MeSH), Ventilation à pression positive (méthodes), Volume courant (MeSH).
- MESH :
- analogues et dérivés : Glycine.
- méthodes : Ventilation à pression positive.
- thérapie : Syndrome de détresse respiratoire de l'adulte.
- traitement médicamenteux : Syndrome de détresse respiratoire de l'adulte.
- usage thérapeutique : Glycine, Inhibiteurs de la sérine protéinase, Monoxyde d'azote, Sulfonamides.
- Décubitus ventral, Essais contrôlés randomisés comme sujet, Humains, Ohio, Taux de survie, Ventilation liquide, Ventilation à haute fréquence, Volume courant.
English descriptors
- KwdEn :
- Glycine (analogs & derivatives), Glycine (therapeutic use), High-Frequency Ventilation (MeSH), Humans (MeSH), Liquid Ventilation (MeSH), Nitric Oxide (therapeutic use), Ohio (MeSH), Positive-Pressure Respiration (methods), Prone Position (MeSH), Randomized Controlled Trials as Topic (MeSH), Respiratory Distress Syndrome, Adult (drug therapy), Respiratory Distress Syndrome, Adult (therapy), Serine Proteinase Inhibitors (therapeutic use), Sulfonamides (therapeutic use), Survival Rate (MeSH), Tidal Volume (MeSH).
- MESH :
- chemical , analogs & derivatives : Glycine.
- chemical , therapeutic use : Glycine, Nitric Oxide, Serine Proteinase Inhibitors, Sulfonamides.
- geographic : Ohio.
- drug therapy : Respiratory Distress Syndrome, Adult.
- methods : Positive-Pressure Respiration.
- therapy : Respiratory Distress Syndrome, Adult.
- High-Frequency Ventilation, Humans, Liquid Ventilation, Prone Position, Randomized Controlled Trials as Topic, Survival Rate, Tidal Volume.
Abstract
In the last 7 years, 14 randomized controlled trials in patients with acute respiratory distress syndrome (ARDS) have shown that: Mechanical ventilation with a tidal volume of 6 mL/kg of predicted body weight is better than mechanical ventilation with a tidal volume of 12 mL/kg of predicted body weight. Prone positioning improves oxygenation but poses safety concerns. A high level of positive end-expiratory pressure does not improve survival. High-frequency oscillatory ventilation is in theory the ideal "lung-protective" method, but its benefits have not been proven. No drug therapy has been shown to improve survival in patients with ARDS. Exogenous surfactant may improve oxygenation but has no significant effect on the death rate or length of use of mechanical ventilation. Low-dose inhaled nitric oxide has no substantial impact on the duration of ventilatory support or on the death rate. Partial liquid ventilation may be beneficial in young patients with acute lung injury or ARDS, although further study is needed to confirm this.
DOI: 10.3949/ccjm.73.3.217
PubMed: 16548446
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Update in ARDS management: recent randomized controlled trials that changed our practice.</title><author><name sortKey="Santacruz, J Fernando" sort="Santacruz, J Fernando" uniqKey="Santacruz J" first="J Fernando" last="Santacruz">J Fernando Santacruz</name><affiliation wicri:level="2"><nlm:affiliation>Department of General Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of General Internal Medicine, The Cleveland Clinic Foundation, OH 44195</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author><author><name sortKey="Diaz Guzman Zavala, Enrique" sort="Diaz Guzman Zavala, Enrique" uniqKey="Diaz Guzman Zavala E" first="Enrique" last="Diaz Guzman Zavala">Enrique Diaz Guzman Zavala</name></author><author><name sortKey="Arroliga, Alejandro C" sort="Arroliga, Alejandro C" uniqKey="Arroliga A" first="Alejandro C" last="Arroliga">Alejandro C. Arroliga</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16548446</idno><idno type="pmid">16548446</idno><idno type="doi">10.3949/ccjm.73.3.217</idno><idno type="wicri:Area/Main/Corpus">000399</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000399</idno><idno type="wicri:Area/Main/Curation">000399</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000399</idno><idno type="wicri:Area/Main/Exploration">000399</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Update in ARDS management: recent randomized controlled trials that changed our practice.</title><author><name sortKey="Santacruz, J Fernando" sort="Santacruz, J Fernando" uniqKey="Santacruz J" first="J Fernando" last="Santacruz">J Fernando Santacruz</name><affiliation wicri:level="2"><nlm:affiliation>Department of General Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of General Internal Medicine, The Cleveland Clinic Foundation, OH 44195</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author><author><name sortKey="Diaz Guzman Zavala, Enrique" sort="Diaz Guzman Zavala, Enrique" uniqKey="Diaz Guzman Zavala E" first="Enrique" last="Diaz Guzman Zavala">Enrique Diaz Guzman Zavala</name></author><author><name sortKey="Arroliga, Alejandro C" sort="Arroliga, Alejandro C" uniqKey="Arroliga A" first="Alejandro C" last="Arroliga">Alejandro C. Arroliga</name></author></analytic><series><title level="j">Cleveland Clinic journal of medicine</title><idno type="ISSN">0891-1150</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Glycine (analogs & derivatives)</term><term>Glycine (therapeutic use)</term><term>High-Frequency Ventilation (MeSH)</term><term>Humans (MeSH)</term><term>Liquid Ventilation (MeSH)</term><term>Nitric Oxide (therapeutic use)</term><term>Ohio (MeSH)</term><term>Positive-Pressure Respiration (methods)</term><term>Prone Position (MeSH)</term><term>Randomized Controlled Trials as Topic (MeSH)</term><term>Respiratory Distress Syndrome, Adult (drug therapy)</term><term>Respiratory Distress Syndrome, Adult (therapy)</term><term>Serine Proteinase Inhibitors (therapeutic use)</term><term>Sulfonamides (therapeutic use)</term><term>Survival Rate (MeSH)</term><term>Tidal Volume (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Décubitus ventral (MeSH)</term><term>Essais contrôlés randomisés comme sujet (MeSH)</term><term>Glycine (analogues et dérivés)</term><term>Glycine (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Inhibiteurs de la sérine protéinase (usage thérapeutique)</term><term>Monoxyde d'azote (usage thérapeutique)</term><term>Ohio (MeSH)</term><term>Sulfonamides (usage thérapeutique)</term><term>Syndrome de détresse respiratoire de l'adulte (thérapie)</term><term>Syndrome de détresse respiratoire de l'adulte (traitement médicamenteux)</term><term>Taux de survie (MeSH)</term><term>Ventilation liquide (MeSH)</term><term>Ventilation à haute fréquence (MeSH)</term><term>Ventilation à pression positive (méthodes)</term><term>Volume courant (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Glycine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Glycine</term><term>Nitric Oxide</term><term>Serine Proteinase Inhibitors</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ohio</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Glycine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Respiratory Distress Syndrome, Adult</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Positive-Pressure Respiration</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Ventilation à pression positive</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Respiratory Distress Syndrome, Adult</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Syndrome de détresse respiratoire de l'adulte</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome de détresse respiratoire de l'adulte</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Glycine</term><term>Inhibiteurs de la sérine protéinase</term><term>Monoxyde d'azote</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>High-Frequency Ventilation</term><term>Humans</term><term>Liquid Ventilation</term><term>Prone Position</term><term>Randomized Controlled Trials as Topic</term><term>Survival Rate</term><term>Tidal Volume</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Décubitus ventral</term><term>Essais contrôlés randomisés comme sujet</term><term>Humains</term><term>Ohio</term><term>Taux de survie</term><term>Ventilation liquide</term><term>Ventilation à haute fréquence</term><term>Volume courant</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the last 7 years, 14 randomized controlled trials in patients with acute respiratory distress syndrome (ARDS) have shown that: Mechanical ventilation with a tidal volume of 6 mL/kg of predicted body weight is better than mechanical ventilation with a tidal volume of 12 mL/kg of predicted body weight. Prone positioning improves oxygenation but poses safety concerns. A high level of positive end-expiratory pressure does not improve survival. High-frequency oscillatory ventilation is in theory the ideal "lung-protective" method, but its benefits have not been proven. No drug therapy has been shown to improve survival in patients with ARDS. Exogenous surfactant may improve oxygenation but has no significant effect on the death rate or length of use of mechanical ventilation. Low-dose inhaled nitric oxide has no substantial impact on the duration of ventilatory support or on the death rate. Partial liquid ventilation may be beneficial in young patients with acute lung injury or ARDS, although further study is needed to confirm this.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16548446</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-1150</ISSN><JournalIssue CitedMedium="Print"><Volume>73</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Cleveland Clinic journal of medicine</Title></Journal><ArticleTitle>Update in ARDS management: recent randomized controlled trials that changed our practice.</ArticleTitle><Pagination><MedlinePgn>217-9, 223-5, 229 passim</MedlinePgn></Pagination><Abstract><AbstractText>In the last 7 years, 14 randomized controlled trials in patients with acute respiratory distress syndrome (ARDS) have shown that: Mechanical ventilation with a tidal volume of 6 mL/kg of predicted body weight is better than mechanical ventilation with a tidal volume of 12 mL/kg of predicted body weight. Prone positioning improves oxygenation but poses safety concerns. A high level of positive end-expiratory pressure does not improve survival. High-frequency oscillatory ventilation is in theory the ideal "lung-protective" method, but its benefits have not been proven. No drug therapy has been shown to improve survival in patients with ARDS. Exogenous surfactant may improve oxygenation but has no significant effect on the death rate or length of use of mechanical ventilation. Low-dose inhaled nitric oxide has no substantial impact on the duration of ventilatory support or on the death rate. Partial liquid ventilation may be beneficial in young patients with acute lung injury or ARDS, although further study is needed to confirm this.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Santacruz</LastName><ForeName>J Fernando</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz Guzman Zavala</LastName><ForeName>Enrique</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Arroliga</LastName><ForeName>Alejandro C</ForeName><Initials>AC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cleve Clin J Med</MedlineTA><NlmUniqueID>8703441</NlmUniqueID><ISSNLinking>0891-1150</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015842">Serine Proteinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>DWI62G0P59</RegistryNumber><NameOfSubstance UI="C069195">sivelestat</NameOfSubstance></Chemical><Chemical><RegistryNumber>TE7660XO1C</RegistryNumber><NameOfSubstance UI="D005998">Glycine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005998" MajorTopicYN="N">Glycine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006612" MajorTopicYN="N">High-Frequency Ventilation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021061" MajorTopicYN="N">Liquid Ventilation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009820" MajorTopicYN="N" Type="Geographic">Ohio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011175" MajorTopicYN="N">Positive-Pressure Respiration</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016684" MajorTopicYN="N">Prone Position</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome, Adult</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015842" MajorTopicYN="N">Serine Proteinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013990" MajorTopicYN="N">Tidal Volume</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>21</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16548446</ArticleId><ArticleId IdType="doi">10.3949/ccjm.73.3.217</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Ohio</li></region></list><tree><noCountry><name sortKey="Arroliga, Alejandro C" sort="Arroliga, Alejandro C" uniqKey="Arroliga A" first="Alejandro C" last="Arroliga">Alejandro C. Arroliga</name><name sortKey="Diaz Guzman Zavala, Enrique" sort="Diaz Guzman Zavala, Enrique" uniqKey="Diaz Guzman Zavala E" first="Enrique" last="Diaz Guzman Zavala">Enrique Diaz Guzman Zavala</name></noCountry><country name="États-Unis"><region name="Ohio"><name sortKey="Santacruz, J Fernando" sort="Santacruz, J Fernando" uniqKey="Santacruz J" first="J Fernando" last="Santacruz">J Fernando Santacruz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrdaDecubitusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000388 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000388 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrdaDecubitusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16548446
|texte= Update in ARDS management: recent randomized controlled trials that changed our practice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16548446" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrdaDecubitusV1
| This area was generated with Dilib version V0.6.37. |  |